FDA grants approval for bluebird’s Zynteglo to treat beta-thalassemia
Pharmaceutical Technology
AUGUST 18, 2022
A custom-made, one-dose gene therapy, Zynteglo is indicated for such patients who need red blood cells (RBCs) transfusions on a regular basis. 0 genotypes. An ex-vivo lentiviral vector (LVV) gene therapy, Zynteglo’s every dose is made by genetically modifying the bone marrow stem cells of the patient to produce functional beta-globin.
Let's personalize your content